Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Many athletes hold unscientific views about benefits of different hydration practices

Nearly half of recreational runners may be drinking too much fluid during races, according to a survey of runners by Loyola University Health System researchers.

3 Sep 2011

Study finds link between long-term dietary patterns and human gut bacteria

"You are what you eat" is familiar enough, but how deep do the implications go? An interdisciplinary group of investigators from the Perelman School of Medicine at the University of Pennsylvania have found an association between long-term dietary patterns and the bacteria of the human gut.

3 Sep 2011

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Bristol-Myers Squibb Company today announced that new data on NULOJIX (belatacept) will be presented at the European Society for Organ Transplantation (ESOT) Congress on September 4 -7, 2011 in Glasgow, Scotland, United Kingdom.

2 Sep 2011

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for RELISTOR Subcutaneous Injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain.

30 Aug 2011

IntraPace to launch new lifestyle management portal and support network at IFSO 2011 congress

IntraPace, Inc., the developer of the innovative abiliti implantable obesity management system, announced today that it will launch its new lifestyle management portal and support network this week at the XVI World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) in Hamburg, Germany.

30 Aug 2011

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Fludrocortisone may help reduce unexplained chronic nausea in children

Heart rate and blood pressure regulation may hold the key to treating unexplained chronic nausea in children. In a new study by researchers at Wake Forest Baptist Medical Center, a drug commonly used to treat a condition known as orthostatic intolerance (OI), which causes dizziness and occasional fainting when patients stand for long periods, was shown to reduce debilitating chronic nausea in patients.

26 Aug 2011

Firazyr receives FDA approval for treatment of HAE acute attacks

The U.S. Food and Drug Administration today approved Firazyr (icatibant) Injection for the treatment of acute attacks of a rare condition called hereditary angioedema (HAE) in people ages 18 years and older.

26 Aug 2011

ICU patients less likely to renew prescriptions for chronic diseases after discharge

Patients often do not renew prescriptions for their chronic diseases after they are released from hospital.

25 Aug 2011

Mylan subsidiary to exclusively offer EpiPen 2-Pak and EpiPen Jr 2-Pak Auto-Injector

Dey Pharma, L.P., a subsidiary of Mylan Inc., today announced that Dey will exclusively offer the EpiPen 2-Pak and EpiPen Jr 2-Pak (epinephrine) Auto-Injector 0.3/0.15 mg, to encourage physicians and patients to follow recommendations by the National Institute of Allergy and Infectious Diseases (NIAID).

24 Aug 2011

United Therapeutics completes treprostinil diethanolamine Phase 3 trial in PAH

United Therapeutics Corporation announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension.

24 Aug 2011

Children of women with HG more likely to suffer from anxiety, bipolar disorder

An extreme form of pregnancy-related nausea and vomiting known as hyperemesis gravidarum (HG) takes a heavy toll on thousands of women each year and can lead to hospitalization and pregnancy termination. But new research suggests pregnant women are not the only victims.

24 Aug 2011

Health Canada accepts Sunovion Pharmaceuticals Canada's lurasidone NDS for review

Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., today announced that the New Drug Submission (NDS) for Lurasidone HCl, for the treatment of adult patients with schizophrenia has been accepted for review by Health Canada. The NDS was submitted to Health Canada in June 2011 and will receive a standard review.

24 Aug 2011

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

23 Aug 2011

Survival for patients with HCC increases with radioembolization

Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed that the procedure is likely to provide survival benefit across different tumor stages, including patients with advanced liver cancer and with limited treatment options.

23 Aug 2011

Santarus, Depomed enter new commercialization agreement for GLUMETZA

Santarus, Inc. and Depomed, Inc. today announced that they have entered into a new commercialization agreement for GLUMETZA (metformin hydrochloride extended release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement that the companies entered into in July 2008.

23 Aug 2011

NovaDel, Rechon enter license and distribution agreement for Zolpimist

NovaDel Pharma Inc., a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced its entry into an exclusive license and distribution agreement with Rechon Life Science AB to manufacture and commercialize Zolpimist® outside the United States and Canada. Zolpimist is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

23 Aug 2011

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated today announced that Health Canada has approved INCIVEK tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

23 Aug 2011

First computerized genome-scale model of cancer cell metabolism

Scientists are constantly on the hunt for treatments that can selectively target cancer cells, leaving other cells in our bodies unharmed.

22 Aug 2011

Nausea News and Research

Further Reading

Many athletes hold unscientific views about benefits of different hydration practices

Study finds link between long-term dietary patterns and human gut bacteria

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

IntraPace to launch new lifestyle management portal and support network at IFSO 2011 congress

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Fludrocortisone may help reduce unexplained chronic nausea in children

Firazyr receives FDA approval for treatment of HAE acute attacks

ICU patients less likely to renew prescriptions for chronic diseases after discharge

Mylan subsidiary to exclusively offer EpiPen 2-Pak and EpiPen Jr 2-Pak Auto-Injector

United Therapeutics completes treprostinil diethanolamine Phase 3 trial in PAH

Children of women with HG more likely to suffer from anxiety, bipolar disorder

Health Canada accepts Sunovion Pharmaceuticals Canada's lurasidone NDS for review

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Survival for patients with HCC increases with radioembolization

Santarus, Depomed enter new commercialization agreement for GLUMETZA

NovaDel, Rechon enter license and distribution agreement for Zolpimist

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

First computerized genome-scale model of cancer cell metabolism

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News